Jim Cramer is concerned about Disney and says there’s reason you should be too even if you don’t own the stock.
Jim Cramer selected 10 market laggards that must bounce in order for the market to continue roaring higher.
Jim Cramer explained why takeover bids are a nasty surprise for the bears.
The iShares NASDAQ Biotechnology ETF was up more than 3 percent on the week, but down nearly 24 percent this year.
The "Fast Money" traders give you 4 trades in the biotech sector.
The Food and Drug Administration approved Gilead's drug for treating chronic hepatitis C virus infection.
The Fast Money traders share their final trades of the day.
CNBC's Meg Tirrell reports on moves in pharmaceutical stocks including Gilead rising on FDA approval for its new combo hepatitis C pill.
CNBC's Sharon Epperson asks money managers Cathie Wood and Chris Retzler which stocks they would bet on in today's health-care landscape.
CNBC's Sharon Epperson asks money managers Cathie Wood, Ark Invest and Chris Retzler, Needham Asset Management about their health-care stock picks.
Biotech stocks rallied after a government report said that Medicare cost-cutting measures will not be triggered this year.
Jim Cramer saw a room for opportunity with one stock that wasn't supposed to drop.
The "Fast Money" traders weighed election risks for biotech after Obama officially endorsed Hillary Clinton.
The "Fast Money" traders give you 4 trades in biotech leading up to this year's controversial election.
"Halftime Report" trader Jon Najarian bought Gilead and Weatherford for his CNBC PRO model portfolio, which is currently up 13 percent on the year.
"FMHR" trader Jon Najarian makes some trades in his Halftime Portfolio including Gilead Sciences and Weatherford International.
The "FMHR" traders discuss the biotech and pharmaceuticals trade and give their best bets for stocks.
New data from eVestment shows that Facebook stock is now ranked 14th among institutional holders.
History shows this is pretty much the "worst thing" you can do, according to value investing legend Joel Greenblatt.
Jim Cramer rattles off his take on caller favorite stocks, including this bank stock that has been blessed by the Oracle of Omaha.